TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12469525

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening-tools for early identification and treatment of sleep-related breathing disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research into pathophysiological mechanisms and therapeutic possibilities of CVD related to OSA
Number of subjects: 0
Study: 10440565

Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (AC), target range INR 1.1 < INR < 1.6
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Regular-intensity anticoagulation (AC), target range INR 2.5 < INR < 3.5
Number of subjects: 729

Group type: COMPARATOR
Intervention: Aspirin 150 mg/d
Number of subjects: 729
Study: 8541368

Group type: EXPERIMENTAL
Intervention: Adelaide Activities Profile (AAP)
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Adelaide Activities Profile (AAP) scales
Number of subjects: 1799
Study: 2334630

Group type: EXPERIMENTAL
Intervention: Org 9426 (250 micrograms kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 9426 (500 micrograms kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (control)
Number of subjects: 0
Study: 479352

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 1250 mg in divided doses
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30293413

Group type: EXPERIMENTAL
Intervention: Vojant™
Number of subjects: 50

Group type: COMPARATOR
Intervention: LigaSure™
Number of subjects: 50
Study: 27927073

Group type: EXPERIMENTAL
Intervention: Team sport intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Individual sport intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 25282598

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone stabilization and taper
Number of subjects: 653
Study: 24803436

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3196

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 3196
Study: 22573231

Group type: EXPERIMENTAL
Intervention: Pelvic-floor biofeedback training (PFBT) once a week for 3 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group receiving verbal instructions to contract the pelvic floor
Number of subjects: 52
Study: 19052048

Group type: EXPERIMENTAL
Intervention: CT group (low-dose CT screening)
Number of subjects: 4104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4104
Study: 17692111

Group type: EXPERIMENTAL
Intervention: Two phone interviews with parents regarding children's passive smoking status and consequences.
Number of subjects: 347

Group type: COMPARATOR
Intervention: Sending a brief note concerning urinary cotinine test results to parents.
Number of subjects: 347
Study: 15215800

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Unstable coronary artery disease population
Number of subjects: 2457
Study: 12236276

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg four times daily for three days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 9846594

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with LCPUFA and vitamin E (FL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unsupplemented infant formula (F)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (FL and F)
Number of subjects: 49
Study: 7813225

Group type: EXPERIMENTAL
Intervention: Low-dose biphasic oral contraceptive (25 micrograms desogestrel and 40 micrograms ethinylestradiol for 7 days, followed by 125 micrograms desogestrel and 30 micrograms ethinylestradiol for 15 days)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Diane-35 (2.0 mg cyproterone acetate and 30 micrograms ethinylestradiol for 21 days)
Number of subjects: 183
Study: 2628304

Group type: EXPERIMENTAL
Intervention: Centpropazine 120 mg and above
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Centpropazine 40 mg daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Centpropazine 80 mg daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 624266

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MAOI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MAOI plus L-tryptophan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31924256

Group type: EXPERIMENTAL
Intervention: Fascial-point acupuncture
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine rehabilitation therapy
Number of subjects: 210
Study: 30221775

Group type: EXPERIMENTAL
Intervention: Real-time auditory feedback during knee repositioning task
Number of subjects: 30

Group type: COMPARATOR
Intervention: No auditory feedback (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Real-time auditory feedback
Number of subjects: 30
Study: 28045285

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 163
Study: 25547237

Group type: EXPERIMENTAL
Intervention: Neutral volar static wrist and MCP splint
Number of subjects: 54

Group type: COMPARATOR
Intervention: Neutral volar static wrist splint
Number of subjects: 54
Study: 23609203

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study: 16908730

Group type: EXPERIMENTAL
Intervention: Argatroban (100 mug/kg bolus followed by 1 mug/kg/min infusion for 48 hours) combined with intravenous rtPA
Number of subjects: 15
Study: 15853274

Group type: COMPARATOR
Intervention: Single visit endodontic procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple visits endodontic procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teeth with vital pulps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teeth with non-vital pulps
Number of subjects: 0
Study: 10715521

Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 299

Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: pa vaccine
Number of subjects: 299
Study: 8857658

Group type: EXPERIMENTAL
Intervention: Mandibular infiltration
Number of subjects: 89

Group type: COMPARATOR
Intervention: Mandibular block
Number of subjects: 89
Study: 1727801

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Esophageal transection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 96

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 96
Study: 6716325

Group type: EXPERIMENTAL
Intervention: Ego threat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study: 31529471

Group type: EXPERIMENTAL
Intervention: Fluorouracil 5% cream
Number of subjects: 624

Group type: COMPARATOR
Intervention: Imiquimod 5% cream
Number of subjects: 624

Group type: COMPARATOR
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Ingenol mebutate 0.015% gel
Number of subjects: 624
Study: 29426695

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 4282

Group type: EXPERIMENTAL
Intervention: Age-adjusted Charlson score of 5 or higher
Number of subjects: 4282

Group type: EXPERIMENTAL
Intervention: Small subgroups (1-5%)
Number of subjects: 4282

Group type: COMPARATOR
Intervention: PIVOT results
Number of subjects: 4282
Study: 28888286

Group type: EXPERIMENTAL
Intervention: Information treatment about funding opportunities for, and returns to, higher education (25-minute session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26094929

Group type: EXPERIMENTAL
Intervention: 2 mg eszopiclone per day
Number of subjects: 78
Study: 24054897

Group type: EXPERIMENTAL
Intervention: Insole with a lateral wedge and additional off‐the‐shelf anti‐pronatory support
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insole with a lateral wedge with no additional support
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition (with standard shoes)
Number of subjects: 15
Study: 20970173

Group type: EXPERIMENTAL
Intervention: Stone Cone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: N‐Trap
Number of subjects: 195

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy without any ureteral occlusive device (Control Group)
Number of subjects: 195
Study: 19700984

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (BTX‐A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16036211

Group type: EXPERIMENTAL
Intervention: Interactive imagery of an animal with a coloured object
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imagining scenes where the animal and coloured object were independent
Number of subjects: 0
Study: 12631596

Group type: EXPERIMENTAL
Intervention: DFMO-PCV
Number of subjects: 249

Group type: COMPARATOR
Intervention: PCV
Number of subjects: 249
Study: 10854004

Group type: EXPERIMENTAL
Intervention: Chronic oestrogen replacement therapy (ERT) 0.625 mg/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen replacement therapy (HRT) ERT plus continuous medroxyprogesterone acetate 5 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study: 8884295

Group type: EXPERIMENTAL
Intervention: Tube splinting (group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No tube splinting (group A)
Number of subjects: 56
Study: 1544194

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.5 MAC, 1.0 MAC, or 1.5 MAC (randomized initial concentration)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC over 90 to 150 min
Number of subjects: 32
Study: 4007193

Group type: EXPERIMENTAL
Intervention: 7.5% homologous patient serum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fetal cord serum
Number of subjects: 100
Study: 31355944

Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg administered for twelve weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29355398

Group type: EXPERIMENTAL
Intervention: Training in using Twitter strategically
Number of subjects: 3
Study: 26107849

Group type: EXPERIMENTAL
Intervention: Entropy measured from intracardiac recordings at the right atrium (RA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Entropy measured from intracardiac recordings at the left atrium (LA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Entropy values at the right atrium (RA)
Number of subjects: 31
Study: 25233383

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: First-line invasive mechanical ventilation
Number of subjects: 211

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation
Number of subjects: 211
Study: 22658954

Group type: EXPERIMENTAL
Intervention: SEEK model of enhanced pediatric primary care
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1119
Study: 20615889

Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 18024869

Group type: EXPERIMENTAL
Intervention: Four additional cycles of third-generation, platinum-doublet treatment (arm A)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Two additional cycles of third-generation, platinum-doublet treatment (arm B)
Number of subjects: 314
Study: 16209966

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5-10 mg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Losartan (25-50 mg)
Number of subjects: 203
Study: 12585142

Group type: EXPERIMENTAL
Intervention: Xiaoyu Tablet (XYT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gastrodine lipid-lowering tablet
Number of subjects: 20
Study: 10512389

Group type: EXPERIMENTAL
Intervention: Mandibular long‐bar overdenture
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hybrid overdenture
Number of subjects: 16
Study: 7862416

Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS) Plus
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dextrose bicarbonate lactated Ringer's solution
Number of subjects: 64
Study: 1772464

Group type: EXPERIMENTAL
Intervention: Hydrotalcite (2 tablets qid, neutralizing capacity 122 mmol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7019454

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine with cerium nitrate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Silver sulfadiazine alone
Number of subjects: 2
Study: 31604061

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hyaluronic acid (8 mL, range 4 to 11 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hyaluronic acid
Number of subjects: 30
Study: 31180160

Group type: EXPERIMENTAL
Intervention: Convex abutment (CX Group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Concave abutment (CV Group)
Number of subjects: 28
Study: 27684740

Group type: EXPERIMENTAL
Intervention: Extended flexible regimen of 20 μg ethinylestradiol and 3 mg drospirenone (EE/DRSPe.flex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24/4 cyclical regimen of the same formulation (EE/DRSP24/4)
Number of subjects: 0
Study: 25711648

Group type: EXPERIMENTAL
Intervention: General psychiatric management (10-session treatment)
Number of subjects: 1
Study: 23612465

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 3206

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 3206

Group type: EXPERIMENTAL
Intervention: FNAB
Number of subjects: 3206

Group type: EXPERIMENTAL
Intervention: Surgery for benign lesions
Number of subjects: 3206

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3206
Study: 21159080

Group type: EXPERIMENTAL
Intervention: Redesigned card
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Centre-based education
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1506
Study: 19808441

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (1 g of cefazolin administered intravenously before the procedure)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo (no antibiotics administered)
Number of subjects: 1000
Study: 17401033

Group type: EXPERIMENTAL
Intervention: Follow-up assessments (extra visit at week 3)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Follow-up assessments (extra visit at week 5)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Two additional follow-up visits
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 14971661

Group type: EXPERIMENTAL
Intervention: Insoluble nickel compounds (Ni3S2, NiS, HT NiO, LT NiO)
Number of subjects: 0
Study: 11252686

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg TID
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 9448064

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) administered to healthy volunteers, specific dosage not mentioned.
Number of subjects: 0
Study: 8180032

Group type: EXPERIMENTAL
Intervention: Granisetron 2 micrograms kg‐1 (group A)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms kg‐1 (group B)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1 (group C)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Granisetron (any dose) with rescue doses
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Granisetron alone (any dose)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 157
Study: 3358901

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg 12 hourly
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg 8 hourly
Number of subjects: 9

Group type: COMPARATOR
Intervention: Theophylline 125 mg 8 hourly
Number of subjects: 9
Study: 29216020

Group type: EXPERIMENTAL
Intervention: LP-pHF (1.9 g protein/100 kcal)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: LP-eHF with synbiotics
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: LP-pHF with synbiotics
Number of subjects: 402

Group type: COMPARATOR
Intervention: Regular protein eHF (2.3 g protein/100 kcal)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: LP-eHF
Number of subjects: 402
Study: 28044986

Group type: EXPERIMENTAL
Intervention: 24-month dual antiplatelet therapy (DAPT)
Number of subjects: 587

Group type: COMPARATOR
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 587
Study: 26136531

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine (control experiments without GLP-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control experiments without GLP-1)
Number of subjects: 10
Study: 23785166

Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketanserin (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21131461

Group type: EXPERIMENTAL
Intervention: 4% lidocaine topical anesthetic cream applied to the face for one hour without occlusion (Group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one half-hour without occlusion (Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one hour without occlusion (Group C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one hour with occlusion (Group D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of all four groups
Number of subjects: 25
Study: 18992629

Group type: EXPERIMENTAL
Intervention: Inpatient and outpatient counseling on smoking cessation and pharmacological protocol
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 277
Study: 16361531

Group type: EXPERIMENTAL
Intervention: FEC50 plus tamoxifen (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2, six cycles every 21 days)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Tamoxifen alone (30 mg/day, 3 years)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: FEC50 plus tamoxifen
Number of subjects: 457

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 457
Study: 12652882

Group type: EXPERIMENTAL
Intervention: Humorous video
Number of subjects: 33

Group type: COMPARATOR
Intervention: Distraction control group (tourism video)
Number of subjects: 33
Study: 10645381

Group type: EXPERIMENTAL
Intervention: Semantic processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked presentation of target items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention interval (immediate, one week, three weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsemantic processing
Number of subjects: 0
Study: 8703299

Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1810331

Group type: EXPERIMENTAL
Intervention: Ketac‐Silver (1 mm placed on the axial wall before amalgam insertion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GC Lining/amalgam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Miracle Mix/amalgam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dispersalloy amalgam alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: No restorations
Number of subjects: 50
Study: 6409690

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg three times a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paracetamol (1 g three times a day)
Number of subjects: 25
Study: 4009965

Group type: EXPERIMENTAL
Intervention: slow-release nifedipine (20 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30032885

Group type: COMPARATOR
Intervention: Ketamine 0 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of mean arterial pressure
Number of subjects: 50
Study: 26867863

Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring (medication dispenser for ribavirin intake)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring and standard-of-care
Number of subjects: 72
Study: 24507481

Group type: EXPERIMENTAL
Intervention: Tailored Activities Program (TAP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Phone-based education sessions (Control)
Number of subjects: 180
Study: 22729797

Group type: EXPERIMENTAL
Intervention: Cognitively oriented behavioural rehabilitation in combination with Qigong
Number of subjects: 107

Group type: COMPARATOR
Intervention: Qigong alone
Number of subjects: 107
Study: 21218677

Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: General activity pacing intervention
Number of subjects: 32
Study: 18496321

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHG) for 8 weeks
Number of subjects: 49
Study: 15705369

Group type: EXPERIMENTAL
Intervention: GnRH-antagonist
Number of subjects: 80

Group type: COMPARATOR
Intervention: GnRH-agonist
Number of subjects: 80